AB 641: Drug-Induced Movement Disorder Awareness Program.
- Session Year: 2025-2026
- House: Assembly
- Latest Version Date: 2025-04-10
Current Status:
Failed
(2026-02-02: From committee: Filed with the Chief Clerk pursuant to Joint Rule 56.)
Introduced
In Committee
Awaiting First Chamber Vote
Passed First Chamber
In Committee
Awaiting Second Chamber Vote
Passed Second Chamber
Enacted
Existing law requires the State Department of Public Health to conduct various programs related to disease prevention and health promotion, including a program for identifying, screening, and providing followup care related to exposure to diethylstilbestrol while pregnant, which can cause fetal abnormalities. Existing law states the intention of the Legislature to fund this program in subsequent fiscal years through the normal budgetary process.
This bill would direct, upon appropriation of funds, as specified, the State Department of Public Health, by January 1, 2027 2028, to develop and administer a program related to drug-induced movement disorder awareness, as specified. The bill would repeal the program on January 1, 2031. 2032. The bill would include related findings and declarations.
Under existing law, the State Department of Public Health is responsible for the administration and oversight of various health care programs. Existing law, the California Osteoporosis Prevention and Education Act, states the intent of the Legislature to raise awareness of the causes of and options for the prevention of osteoporosis, to educate the public regarding the prevention and management of osteoporosis, and to improve management of osteoporosis, thereby minimizing its impact. Existing law sets forth the requirements for administration of the program.
This bill would direct, upon appropriation of funds, as specified, the State Department of Public Health, by or within an unspecified date, January 1, 2027, to develop and administer a program related to drug-induced movement disorder awareness, as specified. The bill would repeal the program on January 1, 2031. The bill would include related findings and declarations.
Under existing law, the State Department of Public Health is responsible for the administration and oversight of various health care programs. Existing law, the California Osteoporosis Prevention and Education Act, states the intent of the Legislature to raise awareness of the causes of and options for the prevention of osteoporosis, to educate the public regarding the prevention and management of osteoporosis, and to improve management of osteoporosis, thereby minimizing its impact. Existing law sets forth the requirements for administration of the program.
This bill would direct, upon appropriation of funds, as specified, the State Department of Public Health, by or within an unspecified date, to develop and administer a program related to drug-induced movement disorder awareness, as specified. The bill would repeal the program on January 1, 2031. The bill would include related findings and declarations.
The Legislature finds and declares the following:
(a)In order to enhance the potential for positive outcomes in mental health treatment, it is essential to provide patients and health care providers with educational information about the importance of screening for and recognizing symptoms of mental health drug-induced movement disorders, develop guidance on clinical standards for treating drug-induced movement disorders, including via telehealth, disorders, and the elimination of bias and reduction of stigma for people living with drug-induced movement disorders related to the treatment of mental health conditions.
(b)Patients receiving treatment with medications for their mental health conditions may be at risk of developing a drug-induced movement disorder. Drug-induced movement disorders, as discussed in the most recent edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), are of frequent importance when mental disorders and other medical conditions are managed with antipsychotic medications. These involuntary movement disorders are caused by medications that help control dopamine, such as first- and second-generation antipsychotics commonly prescribed to treat people living with mental illnesses like schizophrenia, bipolar disorder, and major depression.
(c)Some drug-induced movement disorders, such as tardive dyskinesia, are persistent, irreversible, potentially disabling neurological conditions characterized by uncontrollable repetitive movements of the face, torso, or other parts of the body. While untreated involuntary movements can be stigmatizing and debilitating, the rates of undiagnosed patients living with drug-induced movement disorders remains high.
(d)Awareness of and periodic screenings for movement disorders are fundamental to the proper identification, diagnosis, and timely treatment of drug-induced movement disorders. Recent updates to the American Psychiatric Associations clinical guidelines reflect the importance of screening in people at risk of developing drug-induced movement disorders, but health care and mental health providers, patients, and the public may be unaware of these standards.
(e)Public education and information about drug-induced movement disorders will help health professionals, public safety officials, and the community better understand these disorders, including what causes these types of involuntary movements and their prevalence. This can help reduce stigma by clarifying that some abnormal movements that may be mistaken as a public safety concern are actually uncontrollable physical symptoms of conditions caused by medication used to treat mental illness.
(f)In addition, services provided via telehealth to patients at risk of developing drug-induced movement disorders, such as those treated with antipsychotic medications, should align with existing clinical standards of care. This includes ensuring that at-risk patients are periodically screened and assessed for developing drug-induced movement disorders. The needs of patients living with or at risk of developing drug-induced movement disorders encompass both mental and physical health care, and therefore may require additional considerations when determining the clinical appropriateness of telehealth.
SEC. 2Chapter 5 (commencing with Section 104895.5) is added to Part 3 of Division 103 of the Health and Safety Code, to read:5.Drug-induced movement disorder awareness program104895.5.(a)Upon appropriation by the Legislature or the appropriation of federal funds to the State Department of Public Health for this purpose, the department shall, by January 1, 2028, develop and administer a program to raise awareness about drug-induced movement disorders. The program shall include, but is not limited to, both of the following:
(1)Evidence-based educational information on the importance of screening for and identifying symptoms of drug-induced movement disorders, and the risk factors for developing drug-induced movement disorders.
(2)Education and outreach to eliminate the stigma for people living with drug-induced movement disorders related to the treatment of mental health conditions.
(b)The department may consult with the State Department of Health Care Services and the Behavioral Health Services Oversight and Accountability Commission in implementing this chapter.
(c)This chapter shall remain in effect only until January 1, 2032, and as of that date is repealed.
SEC. 2.Chapter 2 (commencing with Section 125711) is added to Part 8 of Division 106 of the Health and Safety Code, to read:2.Drug-Induced Movement Disorder Awareness Program125711.(a)Upon appropriation by the Legislature or the appropriation of federal funds to the State Department of Public Health for this purpose, the State Department of Public Health shall, by January 1, 2027, develop and administer a program to raise awareness about drug-induced movement disorders. The program shall include, but is not limited to, all of the following:(1)Educational information on the importance of screening for and identifying symptoms of drug-induced movement disorders.(2)The development of guidance on clinical standards for treating drug-induced movement disorders, including for services provided via telehealth.(3)Education and outreach to eliminate stigma for people living with drug-induced movement disorders related to the treatment of mental health conditions.(b)This chapter shall remain in effect only until January 1, 2031, and as of that date is repealed.The Legislature finds and declares the following:
(a)In order to enhance the potential for positive outcomes in mental health treatment, it is essential to provide patients and health care providers with educational information about the importance of screening for and recognizing symptoms of mental health drug-induced movement disorders, develop guidance on clinical standards for treating drug-induced movement disorders, including via telehealth, and the elimination of bias and reduction of stigma for people living with drug-induced movement disorders related to the treatment of mental health conditions.
(b)Patients receiving treatment with medications for their mental health conditions may be at risk of developing a drug-induced movement disorder. Drug-induced movement disorders, as discussed in the most recent edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), are of frequent importance when mental disorders and other medical conditions are managed with antipsychotic medications. These involuntary movement disorders are caused by medications that help control dopamine, such as first- and second-generation antipsychotics commonly prescribed to treat people living with mental illnesses like schizophrenia, bipolar disorder, and major depression.
(c)Some drug-induced movement disorders, such as tardive dyskinesia, are persistent, irreversible, potentially disabling neurological conditions characterized by uncontrollable repetitive movements of the face, torso, or other parts of the body. While untreated involuntary movements can be stigmatizing and debilitating, the rates of undiagnosed patients living with drug-induced movement disorders remains high.
(d)Awareness of and periodic screenings for movement disorders are fundamental to the proper identification, diagnosis, and timely treatment of drug-induced movement disorders. Recent updates to the American Psychiatric Associations clinical guidelines reflect the importance of screening in people at risk of developing drug-induced movement disorders, but health care and mental health providers, patients, and the public may be unaware of these standards.
(e)Public education and information about drug-induced movement disorders will help health professionals, public safety officials, and the community better understand these disorders, including what causes these types of involuntary movements and their prevalence. This can help reduce stigma by clarifying that some abnormal movements that may be mistaken as a public safety concern are actually uncontrollable physical symptoms of conditions caused by medication used to treat mental illness.
(f)In addition, services provided via telehealth to patients at risk of developing drug-induced movement disorders, such as those treated with antipsychotic medications, should align with existing clinical standards of care. This includes ensuring that at-risk patients are periodically screened and assessed for developing drug-induced movement disorders. The needs of patients living with or at risk of developing drug-induced movement disorders encompass both mental and physical health care, and therefore may require additional considerations when determining the clinical appropriateness of telehealth.
SEC. 2.Chapter 2 (commencing with Section 125711) is added to Part 8 of Division 106 of the Health and Safety Code, to read:2.Drug-Induced Movement Disorder Awareness Program125711.(a)Upon appropriation by the Legislature or the appropriation of federal funds to the State Department of Public Health for this purpose, the State Department of Public Health shall, by or within ____, January 1, 2027, develop and administer a program to raise awareness about drug-induced movement disorders. The program shall include, but is not limited to, all of the following:
(1)Educational information on the importance of screening for and identifying symptoms of drug-induced movement disorders.
(2)The development of guidance on clinical standards for treating drug-induced movement disorders, including for services provided via telehealth.
(3)Education and outreach to eliminate stigma for people living with drug-induced movement disorders related to the treatment of mental health conditions.
(b)This chapter shall remain in effect only until January 1, 2031, and as of that date is repealed.
The Legislature finds and declares the following:
(a)In order to enhance the potential for positive outcomes in mental health treatment, it is essential to provide patients and health care providers with educational information about the importance of screening for and recognizing symptoms of mental health drug-induced movement disorders, develop guidance on clinical standards for treating drug-induced movement disorders, including via telehealth, and the elimination of bias and reduction of stigma for people living with drug-induced movement disorders related to the treatment of mental health conditions.
(b)Patients receiving treatment with medications for their mental health conditions may be at risk of developing a drug-induced movement disorder. Drug-induced movement disorders, as discussed in the most recent edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), are of frequent importance when mental disorders and other medical conditions are managed with antipsychotic medications. These involuntary movement disorders are caused by medications that help control dopamine, such as first- and second-generation antipsychotics commonly prescribed to treat people living with mental illnesses like schizophrenia, bipolar disorder, and major depression.
(c)Some drug-induced movement disorders, such as tardive dyskinesia, are persistent, irreversible, potentially disabling neurological conditions characterized by uncontrollable repetitive movements of the face, torso, or other parts of the body. While untreated involuntary movements can be stigmatizing and debilitating, the rates of undiagnosed patients living with drug-induced movement disorders remains high.
(d)Awareness of and periodic screenings for movement disorders are fundamental to the proper identification, diagnosis, and timely treatment of drug-induced movement disorders. Recent updates to the American Psychiatric Associations clinical guidelines reflect the importance of screening in people at risk of developing drug-induced movement disorders, but health care and mental health providers, patients, and the public may be unaware of these standards.
(e)Public education and information about drug-induced movement disorders will help health professionals, public safety officials, and the community better understand these disorders, including what causes these types of involuntary movements and their prevalence. This can help reduce stigma by clarifying that some abnormal movements that may be mistaken as a public safety concern are actually uncontrollable physical symptoms of conditions caused by medication used to treat mental illness.
(f)In addition, services provided via telehealth to patients at risk of developing drug-induced movement disorders, such as those treated with antipsychotic medications, should align with existing clinical standards of care. This includes ensuring that at-risk patients are periodically screened and assessed for developing drug-induced movement disorders. The needs of patients living with or at risk of developing drug-induced movement disorders encompass both mental and physical health care, and therefore may require additional considerations when determining the clinical appropriateness of telehealth.
SEC. 2.Chapter 2 (commencing with Section 125711) is added to Part 8 of Division 106 of the Health and Safety Code, to read:2.Drug-Induced Movement Disorder Awareness Program125711.(a)Upon appropriation by the Legislature or the appropriation of federal funds to the State Department of Public Health for this purpose, the State Department of Public Health shall, by or within ____, develop and administer a program to raise awareness about drug-induced movement disorders. The program shall include, but is not limited to, all of the following:
(1)Educational information on the importance of screening for and identifying symptoms of drug-induced movement disorders.
(2)The development of guidance on clinical standards for treating drug-induced movement disorders, including for services provided via telehealth.
(3)Education and outreach to eliminate stigma for people living with drug-induced movement disorders related to the treatment of mental health conditions.
(b)This chapter shall remain in effect only until January 1, 2031, and as of that date is repealed.
|
Date
|
Status
|
|---|---|
| Feb 2, 2026 | From committee: Filed with the Chief Clerk pursuant to Joint Rule 56. |
| Jan 31, 2026 | Died pursuant to Art. IV, Sec. 10(c) of the Constitution. |
| May 23, 2025 | In committee: Held under submission. |
| Apr 30, 2025 | In committee: Set, first hearing. Referred to suspense file. |
| Apr 21, 2025 | Re-referred to Com. on APPR. |
| Apr 10, 2025 | Read second time and amended. |
| Apr 9, 2025 | From committee: Amend, and do pass as amended and re-refer to Com. on APPR. with recommendation: To Consent Calendar. (Ayes 15. Noes 0.) (April 8). |
| Mar 20, 2025 | Re-referred to Com. on HEALTH. |
| Mar 19, 2025 | From committee chair, with author's amendments: Amend, and re-refer to Com. on HEALTH. Read second time and amended. |
| Feb 24, 2025 | Referred to Com. on HEALTH. |
| Feb 14, 2025 | From printer. May be heard in committee March 16. |
| Feb 13, 2025 | Read first time. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Apr 8, 2025 | Do pass as amended, and be re-referred to the Committee on [Appropriations] with recommendation: To Consent Calendar | Assembly Standing Committee on Health |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
|
Organization
|
Position
|
Date
|
|---|---|---|
| California Access Coalition | ** Support | |
| California Behavioral Health Association | ** Support | |
| California Chronic Care Coalition | ** Support | |
| California Life Sciences Association | ** Support | |
| Mental Health America of California | ** Support |
Date of Hearing: April 30, 2025
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Buffy Wicks, Chair
ABPCA Bill Id:AB 641
Author:(Jeff Gonzalez) – As Amended Ver:April 10, 2025
Policy Committee: | Health | Vote: | 15 - 0 |
|
| ||
|
|
Urgency: No State Mandated Local Program: No Reimbursable: No
SUMMARY:
This bill requires the California Department of Public Health (CDPH), upon appropriation of funds for this purpose, by January 1, 2028, develop and administer a program to raise awareness about drug-induced movement disorders.
Specifically, this bill:
- Requires the awareness program to include:
- Evidence-based educational information on the importance of screening for and identifying symptoms of drug-induced movement disorders, and the risk factors for developing drug-induced movement disorders.
- Education and outreach to eliminate the stigma for people living with drug-induced movement disorders related to the treatment of mental health conditions.
- Evidence-based educational information on the importance of screening for and identifying symptoms of drug-induced movement disorders, and the risk factors for developing drug-induced movement disorders.
- Authorizes CDPH to consult with the Department of Health Care Services and the Behavioral Health Services Oversight and Accountability Commission in implementing this chapter.
- Repeals the provisions of this bill on January 1, 2032.
FISCAL EFFECT:
If funds are appropriated for this bill, CDPH estimates it would require one full-time equivalent position to administer the program and an external contractor with clinical expertise to develop information, materials, and messaging and to support implementation. CDPH estimates implementation costs of $430,000 for fiscal year (FY) 2026-27, $580,000 for FY 2027-28, $480,000 annually for FY 2028-29 through FY 2030-31, and $330,000 for FY 2031-32 until the bill sunsets on January 1, 2032 (General Fund).
COMMENTS:
Purpose. This bill is sponsored by the California Access Coalition. According to the author:
Drug-induced movement disorders, such as Tardive Dyskinesia (TD), affect many Californians who rely on antipsychotic medications to manage mental health conditions. With an estimated 600,000
Americans living with TD, 65% remain unaware of their condition, which can significantly impair their quality of life. TD disproportionately impacts disenfranchised communities, including unhoused populations and veterans, who face compounded barriers to care. AB 641 aims to address this by establishing a public awareness program to combat the stigma surrounding drug-induced movement disorders. The bill will promote early detection, diagnosis, and treatment, while expanding access to vital healthcare services for those who need it most.
TD. TD is a neurological syndrome that involves involuntary movements of the facial muscles, tongue, neck, trunk, and limbs. Noticeable facial movements include: lip-smacking, grimacing or frowning, chewing movements, puffing cheeks, and rapid eye blinking. The most common cause of TD is use of antipsychotic medications, especially if used long-term, but anti-nausea and antidepressant medications can also cause TD. People over 40 years old, women, and Black people are more likely to develop TD. In many cases, TD is not reversible. The author states an estimated 600,000 Americans live with TD, as 25% of patients taking antipsychotic medications can develop TD. The majority of patients who develop TD experience mild symptoms, although a small proportion will develop moderate to severe symptoms. TD can be associated with social withdrawal. Even individuals with mild symptoms can experience adverse effects on quality of life.
According to information provided by the author, the federal Centers for Disease Control and Prevention, Chronic Disease Education and Awareness program offers $6.5 million in fiscal year 2024-25 to support public education initiatives for chronic disease. In 2024, TD was added as a highlighted condition for funding priority. The author expects appropriations language directing the federal Health Resources and Services Administration (HRSA) to prioritize screening to pass in 2025.
Analysis Prepared by: Allegra Kim / APPR. / (916) 319-2081
Date of Hearing: April 8, 2025
ASSEMBLY COMMITTEE ON HEALTH
Mia Bonta, Chair
ABPCA Bill Id:AB 641
Author:(Jeff Gonzalez) – As Amended Ver:March 19, 2025
SUBJECT: Drug-Induced Movement Disorder Awareness Program.
SUMMARY: Requires the California Department of Public Health (DPH), upon appropriation by the Legislature or of federal funds for this purpose, and by January 1, 2027, to develop and administer a program to raise awareness about drug-induced movement disorders. Specifically, this bill:
- Requires DPH, upon appropriation by the Legislature or of federal funds for this purpose, and by January 1, 2027, to develop and administer a program to raise awareness about drug-induced movement disorders to include, at a minimum, the following:
- Educational information on the importance of screening for and identifying symptoms of drug-induced movement disorders;
- The development of guidance on clinical standards for treating drug-induced movement disorders, including for services provided via telehealth; and
- Education and outreach to eliminate stigma for people living with drug-induced movement disorders related to the treatment of mental health conditions.
- Repeals these provisions January 1, 2031.
- Makes Legislative findings and declarations regarding the risks of drug-induced movement disorders.
EXISTING LAW:
- Establishes DPH and directs the department to establish various offices and divisions, including the Office of AIDS, Office of Binational Border Health, the Division of Communicable Disease Control, and the Office of Health Equity. Authorizes DPH to commence and maintain all proper and necessary actions and proceedings to enforce its regulations, enjoin and abate nuisances to public health, and to preserve public health. [Health and Safety Code (HSC) § 131000 et seq.]
- Directs and requests several state entities, such as DPH, the State Department of Health Care Services (DHCS), the University of California, and others, to create awareness, treatment, and research programs for the prevention of various diseases and the promotion of health, including cardiovascular disease, cancer, spinal cord injuries, nutrition, tobacco, and more. [HSC § 104100 et seq.]
FISCAL EFFECT: Unknown. This bill has not yet been analyzed by a fiscal committee.
COMMENTS:
- PURPOSE OF THIS BILL. According to the author, drug-induced movement disorders, such as Tardive Dyskinesia (TD), affect many Californians who rely on antipsychotic medications to manage mental health conditions. The author notes, with an estimated 600,000 Americans living with TD, 65% remain unaware of their condition, which can significantly impair their quality of life. The author states that TD disproportionately impacts disenfranchised communities, including unhoused populations and veterans, who face compounded barriers to care and this bill aims to address this by establishing a public awareness program to combat the stigma surrounding drug-induced movement disorders. The author concludes that the bill will promote early detection, diagnosis, and treatment.
- BACKGROUND.
- Antipsychotic Medications. According to UC Irvine, antipsychotic medications, also known as neuroleptics, are an effective treatment for mental health conditions such as schizophrenia and bipolar disorder. They are categorized into two classes—first-generation, or "typical," antipsychotics, and second-generation, or "atypical," antipsychotics. According to the National Institutes of Health (NIH), first-generation antipsychotics were initially developed in the 1950s primarily for the treatment of psychosis, such as schizophrenia. In addition to psychotic illnesses, first-generation antipsychotics have been approved by the US Food and Drug Administration (FDA) for treating and managing acute mania, agitation, bipolar disorder, Tourette syndrome, and hyperactivity. Second-generation antipsychotics have also been FDA-approved to treat and manage psychosis and treatment-resistant schizophrenia, bipolar disorder, schizoaffective disorder, agitation, and irritability.
NIH also notes that first- and second-generation antipsychotics are used in various neuropsychiatric conditions, which are currently considered off-label. These include behavioral disturbances in dementia, geriatric agitation, depression, eating disorders, personality disorders, insomnia, generalized anxiety disorder, obsessive-compulsive disorder, posttraumatic stress disorder, and substance use and dependence disorders. NIH cautions that for many of these conditions, the evidence is inconclusive, and clinicians should use their judgment when considering the prescription of neuroleptics.
- TD. According to the Cleveland Clinic, TD is a neurological syndrome that involves involuntary movements and taking neuroleptic medications is the main cause of this condition, but other anti-nausea and antidepressant medications can cause it as well. TD causes involuntary movements of the facial muscles, tongue, neck, trunk, and limbs. Noticeable facial movements include: lip-smacking, grimacing or frowning, chewing movements, puffing cheeks, and rapid eye blinking. People over 40 years old, women, and black people are more likely to develop TD. In most cases, TD is not reversible, though medication may help manage symptoms.
“Medication-Induced Tardive Dyskinesia: A Review and Update” noted in The Ochsner Journal in 2017 that while TD is commonly seen in patients who are on long-term treatment with antipsychotic medications, several other classes of medications with different mechanisms are also associated with TD. “Tardive Dyskinesia: Spotlight on Current Approaches to Treatment” from American Psychiatric Publishing in 2021 found that future studies are needed to advance the understanding of the mechanisms underlying TD in order to both develop new, effective treatment agents and discover preventive approaches. Although progress has been made in recent years with the current medications, ultimately these medications target only improvement as opposed to discovering mechanisms that may lead to reversal of these debilitating symptoms. The report also suggests that greater understanding of underlying risk factors for TD may lead to predictive algorithms to identify those at greater risk and help inform physicians’ choice of antipsychotic medication.
According to the American Psychiatric Association, although the majority of patients who develop TD experience mild symptoms, a small proportion will develop moderate to severe symptoms. TD can be associated with social withdrawal and even individuals with mild symptoms can experience negative effects on quality of life.
- California Regulations. Current regulations regarding antipsychotic medications (Section 851 of Title 9 of the California Code of Regulations) provide guidance for the rights of voluntary patients to accept or refuse antipsychotic medications and their right to informed consent. Among other things, the regulations acknowledge the risk of TD and require that the patient must be provided with sufficient information about the medication, including the possible additional side effects which may occur to patients taking such medication beyond three months. The regulations require that the patient be advised that such side effects may include persistent involuntary movement of the face or mouth and might at times include similar movement of the hands and feet, and that these symptoms of TD are potentially irreversible and may appear after medications have been discontinued. Involuntary patients must also be notified of these risks, however they may still be medicated after refusing treatment through procedures laid out in the Lanterman-Petris-Short (LPS) Act.
- SUPPORT. Mental Health America of California (MHAC) says in support of this bill that taking antipsychotic medication comes with its own symptoms and risks, a drug-induced movement disorder being one of them, and that due to a lack of awareness and the unpredictability of developing such a disorder, many individuals may not recognize the symptoms or know when to consult their healthcare provider. MHAC argues that by raising awareness about drug-induced movement disorders, California can ensure that individuals who choose to take antipsychotic medication are well prepared to manage the potential risks.
The California Life Sciences Association (CLSA) says in support of this bill that drug-induced movement disorders are a frequent concern for physicians and patients when prescribing medications to manage mental health issues, and that there is little awareness, lackluster screening, and stigma about these disorders among the public and healthcare providers. CLSA says this bill is imperative to spur action from the state beyond simple recognition of drug-induced movement disorders.
The California Chronic Care Coalition (CCCC) also supports this bill and states that despite their severity, there remains a troubling lack of awareness among healthcare providers and the public about the signs and treatment options for these disorders. CCCC says this bill is not only timely but also imperative to ensure that individuals suffering from drug-induced movement disorders receive the care they need and that increasing awareness and reducing stigma can transform lives by enabling earlier diagnosis and intervention while fostering greater equity in healthcare outcomes for disenfranchised communities.
- AMENDMENTS. Given the content of this bill, the committee may wish to place the Drug-Induced Movement Disorder Awareness Program with other programs within statute regarding disease prevention and health promotion. The committee may also wish to amend the bill to permit DPH to consult with DHCS and the Behavioral Health Services Oversight and Accountability Commission, and provide the DPH with additional time to prepare the program since there is no specified funding source. Finally, the committee may wish to clarify that the bill does not require the development of guidance on clinical standards for treating drug-induced movement disorders, but intends to ensure that state websites providing information to the public are up-to-date with current clinical research.
REGISTERED SUPPORT / OPPOSITION:
Support
California Access Coalition (Sponsor)
California Behavioral Health Association
California Chronic Care Coalition
California Life Sciences Association
Mental Health America of California
Opposition
None on file.
Analysis Prepared by: Logan Hess / HEALTH / (916) 319-2097
Bill Author
Bill Co-Author(s):